This work was supported by a grant-in-aid for scientific research on Health and Labor Sciences Research Grants from the Ministry of Health and Welfare of Japan and an NIDCR grant DE-18310.

None to declare.


OXA, oxacillin; VAN, vancomycin; TEC, teicoplanin; BAC, bacitracin; GEN, gentamicin; ERY, erythromycin; OFX, ofloxacin.

Gene ID in S. aureus MW2.

HK, histidine kinase; RR, response regulator.

Probable intrafamily transmission of a highly virulent CTX-M-3-producing Escherichia coli belonging to the emerging phylogenetic subgroup D2 O102-ST405 clone

Liliana Mihaila1*, Benjamin Wyplosz2, Olivier Clermont3, Louis Garry3, Marie Claire Hipeaux4, Daniel Vittecoq2, Elisabeth Dussaix1, Erick Denamur3 and Catherine Branger3,4

1Laboratoire de Microbiologie, Hôpital Paul Brousse, AP-HP, Villejuif, France; 2Unité de Maladies Infectieuses et Tropicales, Hôpital Paul Brousse, AP-HP, Villejuif, France; 3Faculté de Médecine, Site Xavier Bichat, INSERM U722 and Université Denis Diderot-Paris 7, Paris, France; 4Laboratoire de Microbiologie, Hôpital Louis Mourier, AP-HP, Colombes, France

*Corresponding author. Tel: +33-1-45-59-37-21; Fax: +33-1-45-59-37-24; E-mail: liliana.mihaila@pbr.aphp.fr

Keywords: urinary tract infections, UTIs, extended-spectrum β-lactamases, ESBLs, uropathogenic strains
Sir,

Over the last decade, an explosive spread of CTX-M-type extended-spectrum β-lactamases (ESBLs) in *Escherichia coli* has occurred, both in hospital and community settings. Two phenomena may explain such an epidemic profile: the spread within bacterial strains of the plasmids bearing the antibiotic resistance genes and the spread of bacterial clones bearing the resistance-encoding plasmids. The O25b-ST131 clone (where ST stands for sequence type), belonging to the B2 phylogenetic group, has disseminated all over the world. Moreover, this clone, which is highly virulent, can capture a large panel of ESBL genes. The emergence of such clones constitutes a major concern for public health. We report two members of the same family successively admitted to hospital for a febrile urinary tract infection (UTI) caused by a new emerging ESBL-producing *E. coli* clone.

Patient 1, a diabetic woman in her early 60s, was admitted to hospital for a pyelonephritis unsuccessfully treated with norfloxacin. She was obese and had a history of bariatric surgery 2 years ago. Therapy was switched to a combination of cefotaxime and amikacin. A urine culture taken at admission and screening for faecal carriage revealed an ESBL-positive *E. coli* resistant to ciprofloxacin and trimethoprim/sulfamethoxazole, but susceptible to ceftoxitin, carbapenems, nitrofurantoin and aminoglycosides. The treatment was changed to ertapenem and the patient was managed by outpatient parenteral antimicrobial treatment for 2 weeks. She fully recovered and further urine cultures were sterile.

Patient 2, the son of Patient 1 who was in his early 40s, was admitted 10 days after for a febrile prostatitis. He was obese and had been admitted to another hospital 2 months before for the onset of type 2 diabetes. A urine culture and screening for faecal carriage identified an ESBL-positive *E. coli* with the same antibiotype pattern as the isolate from the mother. The patient was initially prescribed ofloxacin, but this was changed to ertapenem. The patient was discharged on day 6, with 3 weeks of home parenteral antibiotic therapy. He fully recovered and subsequent urine cultures were sterile. The son lived independently, but had regularly visited his mother for dinner during the preceding 6 months and had used her toilet. Neither patient had domestic pets.

A thorough analysis of one urine isolate and one faecal isolate from each patient was performed. The ESBL-producing isolates from the two patients were indistinguishable using enterobacterial repetitive intergenic consensus (ERIC) 1 and 2 PCR (Figure 1) and PFGE (data not shown) methods. The presence of *blaCTX-M-3* was revealed by PCR and sequencing. Phylogenetic analysis by the PCR triplex method and multilocus sequence typing (MLST) using the Pasteur Institute scheme showed that these isolates belonged to the D2 phylogenetic subgroup 1 (ST221), corresponding to ST405 of the Achtman MLST scheme. The isolates exhibited the O102 type pattern as the isolate from the mother. The patient was managed by outpatient antimicrobial treatment for 2 weeks. She fully recovered and further urine cultures were sterile.

Potential mechanisms for the observed strain sharing include host-to-host transmission and acquisition from an external source, such as a food supply or domestic pets. We cannot rule out a common source as we did not investigate the presence of ESBL-positive *E. coli* in food, but the temporal pattern of their UTIs suggests a transmission from the mother to the son and the development of the infection from the commensal faecal reservoir. Neither patient had a history of prior antimicrobial use and, despite one hospitalization for each patient in the past 2 years, independent acquisition of an ESBL strain from distinct sources (especially of the same pulsotype) seems unlikely. Although both patients had diabetes, an underlying risk factor for complications of UTIs, neither of them had a previous history of febrile UTI. The strain appears to be particularly virulent, as inferred from two lines of evidence, namely the number and types of virulence genes (seven genes coding for adhesins, siderophores, toxins and protectins) and the mouse lethality assay. Recent studies indicate that the present D2 O102-ST405 *E. coli* is an emerging clone, responsible, like the O25b-ST131 clone, for the worldwide spread of *blaCTX-M* genes. This clone appears to pose the double threat of multidrug resistance and substantial extraintestinal virulence, in addition to its colonization and transmission ability. This makes its emergence and dissemination particularly concerning. New approaches to prevention, detection and management will be needed for this and similar clones.

**Figure 1.** Typing of *E. coli* isolates using ERIC-1 PCR (a) and ERIC-2 PCR (b). λ, DNA molecular weight marker, Euroladder (Eurobio); lanes 1 and 2, *E. coli* isolates from urine and rectum of patient 1; lanes 3 and 4, *E. coli* isolates from urine and rectum of patient 2.

**Funding**

This study was carried out as part of our routine work and partly funded by a grant from the Assistance Publique-Hôpitaux de Paris (Contrat d’Initiation à la Recherche Clinique 05103).

**Transparency declarations**

None to declare.
Sir,

The emergence and dissemination of Klebsiella pneumoniae strains harbouring carbapenemases is a serious concern. Klebsiella pneumoniae carbapenemase (KPC) enzymes belong to molecular class A and are able to hydrolyse most β-lactams including carbapenems. Since the initial report of a KPC β-lactamase from a strain of K. pneumoniae in 1996, KPC producers have been reported from various geographical regions. Current reports indicate that KPC-producing isolates are widespread in China, Israel, Greece, South America and the USA, where the epidemiology of KPC in the hospital setting is changing.1 Fortunately, these strains are still rare in western and northern Europe, but their detection remains difficult.2

Since 2003, patients hospitalized in the surgical ward of our hospital have been systematically screened on admission and weekly thereafter for intestinal carriage of bacteria producing extended-spectrum β-lactamases (ESBLs) and carbapenemases by plating rectal swabs on Drigalski agar containing 0.5 mg/L cefotaxime and MacConkey agar containing 2 mg/L ceftazidime (AES Laboratoire, Combourg, France). We report here four patients with K. pneumoniae producing KPC-2 and SHV-12. The first case was a patient transferred in July 2009 from Crete for treatment of recurrent angiocholitis on a biliary stent. The patient was negative on the day of admission, but 3 days later a further stool sample grew with ESBL-producing K. pneumoniae. This first isolate was not suspected to produce a carbapenemase since testing for susceptibility to imipenem using a disc diffusion method showed a diameter of 24 mm and an MIC of 1.5 mg/L by Etest (Bio-Rad, Marne la Coquette, France), both considered as susceptible according to the national recommendations of the Antibiotic Committee of the French Society for Microbiology.3 However, in September, KPC-producing K. pneumoniae were isolated from three further patients (two from biliary fluid and one from tracheal fluid) hospitalized in the same ward at the same time. As KPC-producing K. pneumoniae are exceptional in France and described only in patients transferred from abroad (particularly Greece and Israel), it was decided to re-investigate all ESBL-producing K. pneumoniae isolated over the previous 6 months and to screen for carbapenemase production using the modified Hodge test and PCR. The only strain that was also positive for bladisc and which matched the three known KPC-positive isolates was the one isolated in July from the patient from Crete, who was thus potentially the index case. An epidemiological study (data not shown) revealed opportunities for cross-transmission to have occurred between the four patients.

This outbreak underlines the difficulty of identifying KPC-mediated carbapenem resistance using routine methods. The K. pneumoniae isolates from the latter three patients showed reduced susceptibility to imipenem, with a diameter of 21 mm, considered to indicate an intermediate level of resistance, an MIC of 2 mg/L and small colonies growing inside the zone of inhibition. All isolates, including the strain recovered from the Greek patient, exhibited resistance to other antibiotics tested: fluoroquinolones, tobramycin, amikacin and co-trimoxazole. The isolates were only susceptible to colistin and gentamicin. Using the modified Hodge test and EDTA-disc synergy,4 all isolates were phenotypically positive for carbapenemase production, but negative for metallo-β-lactamase (MBL) production. ESBL screening tests using the double disc diffusion test between clavulanic acid and third-generation cephalosporins showed a synergy between ceftazidime or cefepime and clavulanic acid.

References

J Antimicrob Chemother 2010
doi:10.1093/jac/dkq132
Advance publication 11 May 2010

Outbreak of Klebsiella pneumoniae producing KPC-2 and SHV-12 in a French hospital

Najiby Kassir-Chikhani1*, Dominique Decré2, Philippe Ichai3, Christian Sengelin1, Delphine Geneste2, Liliana Mihaila1, Elisabeth Dussaix1 and Guillaume Arlet4

1Microbiology Laboratory, AP-HP Hôpital Paul Brousse, Villejuif 94804, France; 2AP-HP Hôpital Saint-Antoine and Faculté de Médecine, Université Pierre et Marie Curie Paris 6, Paris, France; 3AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif 94804, France; 4AP-HP Hôpital Tenon and Faculté de Médecine, Université Pierre et Marie Curie Paris 6, Paris, France

*Corresponding author. Tel: +33-1-45-59-37-20; Fax: +33-1-45-59-37-24; E-mail: najiby.kassir-chikhani@ppr.ap-hop-paris.fr

Keywords: carbapenemases, nosocomial infections, cross-transmission